Overall survival for patients with acute lymphoblastic leukemia—by hematologic response.

This analysis of overall survival by best achieved hematologic response on treatment included 14 patients with CHR or marrow response, 15 patients with partial response, and 14 patients who were treated for at least 4 weeks but did not have documented response (5 patients were excluded). Whereas median survival was 9.2 months for patients who had CHR/marrow response and 7.1 months for patients with partial response, all of the nonresponder died and their median survival was only 3.6 months (P < .001).